Incidence and prevalence of medication-induced osteoporosis: evidence-based review
Author:
- 1 July 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (4) , 435-441
Abstract
(1) While a number of medications have been shown to induce bone loss, the actual incidence and prevalence of medication-induced osteoporosis has not been well quantified. (2) Oral corticosteroids contribute to an increased prevalence of osteoporosis and an increased incidence of fracture in a number of different populations. The increased incidence of fracture in patients receiving inhaled corticosteroids for respiratory disease may be attributed to disease pathogenesis rather than the effects of medication. (3) Other therapies that increase the incidence and/or prevalence of medication-induced osteoporosis and fracture include androgen-deprivation therapy, aromatase inhibitors, protease inhibitors, selective serotonin reuptake inhibitors and prolactin-raising antiepileptic agents. (4) It is difficult to make definitive conclusions on the actual increase in the prevalence and/or incidence of osteoporosis in patients receiving certain medications, as values are often reported differently and studies are mainly retrospective and are therefore open to inherent selection biases and other confounders. Furthermore, there is little available information as to whether specific medications within a class are associated with a higher rate of bone disease than others.Keywords
This publication has 37 references indexed in Scilit:
- Fracture risk in Danish men with prostate cancer: a nationwide register studyBJU International, 2007
- Fracture risk in users of oral anticoagulants: A nationwide case-control studyInternational Journal of Cardiology, 2007
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled studyThe Lancet Oncology, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fracturesLeukemia & Lymphoma, 2007
- High-dose corticosteroid exposure and osteoporosis intervention in adultsAnnals of Allergy, Asthma & Immunology, 2006
- Pathogenesis of Osteopenia/Osteoporosis Induced by Highly Active Anti‐Retroviral Therapy for AIDSAnnals of the New York Academy of Sciences, 2006
- Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005
- Aromatase Inhibitors and Bone Loss: Risks in PerspectiveJournal of Clinical Oncology, 2005